Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 1/9/23 → 11/30/24 |
Financiación
- Kinnate Biopharma Incorporated: 27.721,00 US$
22-MULTI-53-KB-PMC : A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors, KN-8701
- Arnold, Susanne M (PI)